What is Geneoscopy?
Geneoscopy Inc. operates at the intersection of biotechnology and clinical diagnostics, focusing on the detection of colorectal cancer and precancerous adenomas. The company's core innovation utilizes seRNA to identify lesions with higher sensitivity than existing noninvasive screening methods. Having received Breakthrough Device Designation from the U.S. FDA, Geneoscopy is effectively addressing a critical gap in preventative oncology. By providing a more accurate, patient-friendly alternative to traditional screening, the company is poised to significantly reduce morbidity rates associated with gastrointestinal malignancies, establishing itself as a high-authority player in the diagnostic landscape.
How much funding has Geneoscopy raised?
Geneoscopy has raised a total of $217.1M across 4 funding rounds:
Series A
$6.9M
Debt
$150K
Series B
$105M
Series C
$105M
Series A (2019): $6.9M with participation from Cultivation Capital, Lightchain Capital LLC, and NT Investments
Debt (2020): $150K led by PPP
Series B (2021): $105M supported by Lightchain and Nt Investment Academy
Series C (2025): $105M featuring Tri Locum Partners, Morningside Ventures, Lightchain Capital, Bio-Rad Laboratories, Mercy Health, Labcorp, Granger Management, and PETRICHOR Group
Key Investors in Geneoscopy
Cultivation Capital
A venture capital firm that invests in young companies with transformative ideas across various industries, including life sciences and software, providing capital resources to help startups navigate hyper growth.
Lightchain
A UK-based firm specializing in person-focused IT delivery and technology adoption, bringing extensive experience from healthcare and research sectors to support organizational growth.
Lightchain Capital
A venture capital fund that specializes in investing in early-stage life sciences companies, dedicated to supporting innovations aimed at improving patient outcomes in cancer treatment.
What's next for Geneoscopy?
Following this major enterprise-level funding, Geneoscopy is expected to prioritize the scaling of its diagnostic platform and the expansion of its clinical footprint. The strategic backing from industry-leading partners will likely facilitate the transition from late-stage clinical validation to broad market adoption. As the company navigates the regulatory and commercialization phases, the focus will remain on integrating its seRNA technology into standard clinical workflows, thereby enhancing diagnostic precision for healthcare providers and improving patient outcomes on a global scale.
See full Geneoscopy company page
